Two new studies by an international team of researchers report progress in using stem cells to develop new therapies for Pelizaeus-Merzbacher disease (PMD), a rare genetic condition affecting boys that can be fatal before 10 years of age. Often diagnosed at birth with symptoms of weakness and breathing difficulties, the progressive neurological problems in PMD
Interview with Dr. John Kennedy chief of the division of foot and ankle surgery and professor in the department of orthopedic surgery at NYU Langone in New York City. Here, Dr. Kennedy shares his insight into the future of platelet-rich plasma and stem cell therapy in sports medicine. Question: How do you see platelet-rich plasma
The number of cancer cell therapies has increased considerably over the last few years.1 There are several different types of cellular therapies, including chimeric antigen receptor (CAR) T cells, multiple tumor-associated antigen-specific T cells (TAA-T), natural killer (NK)-based therapies and T-cell therapies based on novel technologies like CRISPR.1 Amongst the different types of cell therapies in development,
Source ALS News Today Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease and Lou Gehrig’s disease, is a rare condition characterized by the degeneration of nerve cells that control voluntary muscles. The disease leads to gradually worsening symptoms that include muscle weakness, twitching, and stiffness. As more of these nerve cells, or motor neurons, are lost,
Two critical reviews examine the current status of biologic approaches for common shoulder and elbow problems. The authors discuss areas where the current evidence base is weak or controversial and recommend where further studies are required. The utilization of stem cell therapies for augmentation of tissue healing has far outpaced the supporting scientific and clinical
Stem cell therapy, or stem cell transplant, is an emerging yet controversial treatment approach for multiple sclerosis (MS). While some data uphold it as one of the most efficacious MS treatments, to date there have been no controlled studies comparing it to conventional medicines and providing more robust evidence regarding its safety and clinical benefit. Under the topic
The Italian biotech Genenta Science, a spin-out from San Raffaele Hospital has raised €13.2M in a private round to fund two ongoing phase I/II trials of its stem cell therapy Temferon for blood and brain cancer. Genenta Science will use the money to fund two European phase I/II trials, which the company launched in March. One
Pluripotent stem cells (PSCs) represent an attractive cell source for treating muscular dystrophies (MDs) since they easily allow for the generation of large numbers of highly regenerative myogenic progenitors. Using reprogramming technology, patient-specific PSCs have been derived for several types of MDs, and genome editing has allowed correction of mutations, opening the opportunity for their
A Chicago-based center that has long operated a clinical trial program for stem cell therapies, has stopped recruiting further patients as its chief, Richard Burt, leaves for a research sabbatical. Source The Scientist A pioneering stem cell clinical trial program in the US is closing up shop, a surprise move for what had appeared to
Magenta Therapeutics, a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advance Therapy (RMAT) designation for MGTA-456, a one-time cell therapy for the treatment of multiple inherited metabolic disorders. “This RMAT designation was based
